Data Bridge Market Research analyses that the psoriatic arthritis (PsA) market was valued at USD 11.26 billion in 2021 and is expected to reach USD 23.10 billion by 2029, registering a CAGR of 9.40% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Psoriatic arthritis is a type of arthritis that affects some people who have psoriasis, a skin ailment marked by red areas and silvery scales. The majority of patients get psoriasis first and then get psoriatic arthritis later; however joint issues might start before the skin patches do. The main indications and symptoms of psoriatic arthritis include joint pain, stiffness, and edema. Psoriatic arthritis can strike any region of your body, including your fingertips and spine, and symptoms can range from moderate to severe. Psoriatic arthritis can affect either one or both sides of the body's joints.
View Detailed Report@ https://www.databridgemarketresearch.com/reports/global-psoriatic-arthritis-psa-market
Psoriatic arthritis (PsA) is an inflammatory condition that affects the joints and the areas where tendons and ligaments link to bone. Psoriatic arthritis doesn't have a cure. Controlling inflammation in affected joints to avoid joint pain and impairment and controlling skin involvement are the main goals of treatment. Prescription pharmaceuticals known as disease-modifying antirheumatic drugs are one of the most common treatments (DMARDs). For those with mild psoriatic arthritis, nonsteroidal anti-inflammatory drugs (NSAIDs) can help alleviate pain and inflammation. Artificial metal and plastic joints can be used to replace some of the joints that have been significantly destroyed by psoriatic arthritis.
Drivers
- Rise in the prevalence of psoriatic arthritis (PsA)
The rising prevalence of psoriatic arthritis (PsA) is a major factor driving the psoriatic arthritis (PsA) market's growth rate. Psoriatic arthritis is a degenerative disease that is linked to psoriasis. The condition can cause irreparable joint damage if not treated properly and promptly. Although the specific cause of the disease is unknown, research reveals that genetic factors are responsible for approximately 40% of cases.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of psoriatic arthritis (PsA) market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness about the will expand the psoriatic arthritis (PsA) market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of psoriatic arthritis (PsA) market. Along with this, the rising geriatric population and surge in biological therapy approval will enhance the market's growth rate.
Recent Development
- In December 2021, AbbVie announced the U.S. Food and Drug Administration (FDA) approval of RINVOQ (upadacitinib; 15 mg, once daily) for treating adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. RINVOQ is a JAK inhibitor that is being researched for use in various immune-mediated inflammatory disorders. RINVOQ showed stronger inhibitory potency for JAK-1 compared to JAK-2, JAK-3, and TYK-2 in enzymatic and cellular studies.
Competitive Landscape and Psoriatic Arthritis (PsA) Market Share Analysis
The psoriatic arthritis (PsA) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to psoriatic arthritis (PsA) market.
Some of the major players operating in the psoriatic arthritis (PsA) market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (U.K.)
- Johnson Johnson Private Limited (U.S.)
- Bayer AG (Germany)
- Merck Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- Cadila Pharmaceuticals (India)
- Eli Lilly and Company (U.S.)
- LEO Pharma A/S (Denmark)
- Cipla Inc. (U.S.)
- Aurobindo Pharma (India)
- Lupin (India)
- Sumitomo Corporation (Japan)
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- [email protected]
